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Acute and chronic effects of cannabinoids on human cognition-a
systematic review
Abstract
Cannabis use has been associated with impaired cognition during acute intoxication as well as in the
unintoxicated state in long-term users. However, the evidence has been mixed and contested, and no
systematic reviews of the literature on neuropsychological task-based measures of cognition have been
conducted in an attempt to synthesize the findings. We systematically review the empirical research published
in the past decade (from January 2004 to February 2015) on acute and chronic effects of cannabis and
cannabinoids and on persistence or recovery after abstinence. We summarize the findings into the major
categories of the cognitive domains investigated, considering sample characteristics and associations with
various cannabis use parameters. Verbal learning and memory and attention are most consistently impaired by
acute and chronic exposure to cannabis. Psychomotor function is most affected during acute intoxication,
with some evidence for persistence in chronic users and after cessation of use. Impaired verbal memory,
attention, and some executive functions may persist after prolonged abstinence, but persistence or recovery
across all cognitive domains remains underresearched. Associations between poorer performance and a range
of cannabis use parameters, including a younger age of onset, are frequently reported. Little further evidence
has emerged for the development of tolerance to the acutely impairing effects of cannabis. Evidence for
potential protection from harmful effects by cannabidiol continues to increase but is not definitive. In light of
increasing trends toward legalization of cannabis, the knowledge gained from this body of research needs to be
incorporated into strategies to minimize harm.
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Review
Acute and Chronic Effects of Cannabinoids on
Human Cognition—A Systematic Review
Samantha J. Broyd, Hendrika H. van Hell, Camilla Beale, Murat Yücel, and Nadia Solowij
ABSTRACT
Cannabis use has been associated with impaired cognition during acute intoxication as well as in the unintoxicated
state in long-term users. However, the evidence has been mixed and contested, and no systematic reviews of the
literature on neuropsychological task-based measures of cognition have been conducted in an attempt to synthesize
the findings. We systematically review the empirical research published in the past decade (from January 2004 to
February 2015) on acute and chronic effects of cannabis and cannabinoids and on persistence or recovery after
abstinence. We summarize the findings into the major categories of the cognitive domains investigated, considering
sample characteristics and associations with various cannabis use parameters. Verbal learning and memory and
attention are most consistently impaired by acute and chronic exposure to cannabis. Psychomotor function is most
affected during acute intoxication, with some evidence for persistence in chronic users and after cessation of use.
Impaired verbal memory, attention, and some executive functions may persist after prolonged abstinence, but
persistence or recovery across all cognitive domains remains underresearched. Associations between poorer
performance and a range of cannabis use parameters, including a younger age of onset, are frequently reported.
Little further evidence has emerged for the development of tolerance to the acutely impairing effects of cannabis.
Evidence for potential protection from harmful effects by cannabidiol continues to increase but is not definitive. In
light of increasing trends toward legalization of cannabis, the knowledge gained from this body of research needs to
be incorporated into strategies to minimize harm.
Keywords: Attention, Brain, Cannabis, Cognition, Executive function, Memory
http://dx.doi.org/10.1016/j.biopsych.2015.12.002
Shifts in public opinion and policies toward legalization of
cannabis are poised to result in an increase in the prevalence
of cannabis use beyond the 178 million users estimated to
exist today (1–3). Although most individuals who try cannabis
do not go on to use it regularly (1,2), individuals who do so risk
adverse effects to physical and mental health (4). Negative
sequelae that have been attributed to regular and prolonged
cannabis use include alterations to brain morphology (5–7) and
function (8–11); psychosis risk (12,13); poor psychosocial
outcomes (4,14–17); and impaired cognition, especially defi-
cits in attention, learning and memory (18–21), and executive
functions (9,22). Morphological and connectivity changes in
brain structures with high amounts of cannabinoid receptors
(e.g., hippocampus, prefrontal cortex, cerebellum) (23) may
mediate observed cognitive deficits in cannabis users (5–7,
9–11,24), although direct structure/function relationships are
not readily demonstrated.
A substantial number of studies have been published in
recent years, prompted by renewed interest in understanding
the effects of cannabis on the brain partly as a result of
mounting evidence for links between cannabis use and
psychosis (25–28) and recognition of similarities between
cognitive impairment in cannabis users and deficits observed
in patients with schizophrenia (19). Interest has emerged in
examining the effects of different compounds within cannabis
plant matter, specifically (2)-trans-Δ9-tetrahydrocannabinol
(THC), the primary psychoactive constituent considered to
be psychotogenic, and cannabidiol (CBD), the second most
abundant cannabinoid, shown to have antipsychotic proper-
ties (29) and to attenuate the psychotogenic effects of THC,
with opposite effects on brain function (30). Recent critical
reviews have focused on neuroimaging outcomes from acute
cannabinoid challenge (9,31) and on brain morphology in
chronic users (5,7,32). However, to date, the literature on
neuropsychological task-based measures of cognition has not
been examined in the form of a systematic review. We
systematically review the empirical research published in the
past decade. We identify core themes that have emerged from
the recent literature or continue to plague this field and study
limitations and future directions for this research area.
METHOD
This systematic review was conducted in accordance with
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines (Figure 1) (33). The search strategy and
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data extraction are detailed in Supplement 1, and selection
criteria, resulting in 105 studies included for review, are
provided in the legend of Figure 1. From each study, we
extracted participant demographics (age, sex, IQ), cannabis
use metrics (e.g., age of onset and duration, frequency, and
quantity of use), period of abstinence before testing, extent of
other substance use (including alcohol and tobacco), dosing
details for acute administration studies, cognitive domains
investigated, experimental tasks employed, and key cognitive
findings. The primary results of interest for qualitative syn-
thesis of findings were group differences in performance and
associations with cannabis use metrics.
RESULTS
We provide a summary appraisal of findings organized by
primary cognitive domain in order of evidential strength from
most to least consistently impaired. A more detailed account
of findings from all studies is provided in Supplement 1, and
detailed data extracted from each article are tabulated in Table
S1 in Supplement 2. Within each cognitive domain, we
address first acute administration studies, then studies of
chronic exposure to cannabis, followed briefly by absti-
nence studies. Further consideration is given to the important
issue of persistence or recovery of function separately in the
Discussion. Table 1 provides a qualitative summary of findings
across all cognitive domains examined.
Memory
Memory function has been the most consistently impaired
cognitive domain affected by cannabis, and studies from the
past 10 years continue to extend the evidence base. The most
extensive evidence for impairment is within verbal learning and
memory.
Verbal Learning and Memory. Most often measured
using word list learning tasks, with several immediate and
delayed recall trials and a recognition trial, verbal learning and
memory tasks have been identified as particularly sensitive to
the acute (20,34,35) and chronic (18) effects of cannabis.
Further clear evidence has emerged for impairing effects of
acute intravenous (IV) THC (36–40), vaporized cannabis (41,42)
and oral nabilone (43) on immediate and delayed recall and
sometimes recognition accuracy. Predosing with CBD or
greater CBD content in cannabis may protect against some
THC-induced verbal learning and memory deficits (40,44).
Impaired verbal learning and memory continues to be con-
sistently observed in chronic cannabis users, including ado-
lescents (45–47) and young adults (48–52) [with some
Figure 1. Preferred Reporting Items
for Systematic Reviews and Meta-
Analyses flow diagram for systematic
search and identification of studies
meeting inclusion criteria for systema-
tic review. Selection criteria were as
follows: 1) neuropsychological or cog-
nitive experimental tasks administered
to regular or former cannabis users or
after acute administration of cannabis
or synthetic or phytocannabinoid
compounds; 2) cannabis (or cannabi-
noids) as the primary drug of interest;
and 3) human participants. Exclusion
criteria were as follows: 1) studies in
which cannabis was not the primary
drug of concern; 2) questionnaire
(trait) measures of cognition; 3) major
psychopathology or neurologic condi-
tions within assessed sample; 4)
animal research; 5) neuroimaging,
electrophysiologic, or autonomic
measures as primary outcome vari-
ables; 6) treatment (e.g., cognitive-
behavioral therapy) as the primary
focus; 7) real-world multiplex tasks
requiring simultaneous use and inte-
gration of multiple aspects of cogni-
tion, such as driving; and 8) case
studies.
Records after duplicates removed 
(n = 356)
Full text records screened
(n = 356)
Records excluded 
(n = 260)
Studies included in 
qualitative synthesis 
(n = 105)
Records after titles assessed in 
PubMed (n = 316)
Records after titles assessed in 
Scopus (n = 225)
Records identified through PubMed
(n = 3021)
Records identified through Scopus
(n = 3220)
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Table 1. Strength and Consistency of Evidence for Impairment Associated With Acute and Chronic Cannabis Use and for Recovery of Function With Abstinence
From Research Published in the Past Decadea
Number of Studies
Cognitive Domain Acuteb Chronicb
Persistence
With
Abstinenceb
Pertinent Cannabis Use
Parameters Acute Chronic Abstinence
Memory
Verbal learning and
memory
111 111 12 Frequency; lifetime use;
duration; age of onset;
sex
11 (36–44,77,87) 20 (44–58,60–62,66,142) 9 (55,57,60,63–67,95)
Working memory 12 12 12 Frequency; lifetime use;
recency; sex
20 (36–40,42,43,68–78,88,143) 16 (46,48,49,51–53,55,57,
79–84,115,119)
7 (55,57,64,65,67,79,85)
Other memory function 1 12 2 Age of onset; frequency;
recency
2 (42,144) 8 (45,49,78–80,119,144,145) 4 (63,65,79,95)
Attention
Attention 111 111 12 Dose; age of onset; length
of abstinence;
withdrawal effects
16 (36,37,39,42,43,68,70,71,76,77,
86–90,143)
14 (45,46,54,55,57,61,79–81,84,
91–94)
10 (55,57,63,64,67,79,91–
93,95)
Attentional bias 1 111 NA Craving; dependence;
frequency; CBD
1 (102) 7 (96–102) None
Psychomotor Function 111 1 1 18 (37,42,43,68,70,73,74,76,77,89,90,
103–107,143,146)
10 (46,48,51,54,57,66,78,80,91,108) 6 (57,63–65,67,91)
Executive Function
Planning, reasoning,
interference control,
and problem solving
12 12 12 Neurodevelopmental stage;
age of onset; frequency
12 (37–41,77,86,89,103,104,106,109) 23 (46,48,52–54,57,60,61,66,78,
81–84,93,98,110–115,147)
9 (57,60,63–
65,67,85,93,95)
Inhibition 11 12 NA Frequency; task complexity 5 (42,89,103,104,109) 9 (45,50,54,56,82,110,116–118) None
Verbal fluency 2 12 12 3 (36,38,44) 6 (44,48,51,53,54,61) 4 (65,67,93,119)
Time estimation 12 2 2 6 (73,74,77,86,148,149) 1 (55) 1 (55)
Decision Making 1– 1– 2 Age of onset; lifetime
exposure; frequency;
cannabis use disorder
7 (103,105,106,109,120–122) 17 (45,48,50,56,78,82,84,94,113,116,
117,123–126,128,150)
3 (85,127,128)
CBD, cannabidiol; NA, not available (not investigated).
aThe prevalence of studies focused on acute vs. chronic effects is unequal, as is the focus on individual cognitive domains; strength metrics are based on qualitative interpretation of the
literature, subjectively weighed on greater or lesser evidence for impairment across the published studies, considering the number of studies conducted and their quality (e.g., design, sample
size), reached by consensus between the authors of this review.
b111, strong and largely consistent evidence for impairment; 11, moderate evidence for impairment; 1, weak evidence for impairment, being based on only a small number of studies;
12, mixed evidence; 2, little or no evidence for impairment.
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exceptions (53, 54)] and even in only occasional users (55).
Significant associations between poorer performance in reg-
ular users and frequency, quantity, duration, and age of onset
of cannabis use have been reported (47,49,56–58). Consistent
with previous findings (59), long-term users appear to be more
affected than short-term users (60,61). One study reported
greater impairment associated with higher THC compared with
CBD exposure (62). Improvement (63) or recovery (55,57,
64–66) with abstinence has been observed in some studies
or indices, but not others (64,65,67) (see Supplement 1 and
further on).
Working Memory. Whether working memory is impaired by
cannabis is less clear, possibly because of the wide range of
different working memory tasks employed. Acute administra-
tion of THC, dronabinol, or nabilone affected working memory
inconsistently across Sternberg, delayed matching to sample,
spatial or numeric working memory, n-back, digit recall, and
digit span tasks (36–40,42,43,68–78). Similarly, chronic can-
nabis use was shown to impair working memory in young
adults on immediate recall (79), verbal reasoning (80), and
verbal n-back (81) working memory tasks, but not on spatial
working memory (48,82) or digit span (52,53), whereas spatial
working memory was impaired in adolescent users (46),
suggestive of differential effects in the developing brain. In
older users, two studies reported no impairment on letter-
number sequence and spatial span tests of the Wechsler
Memory Scale (83) or on an n-back task (84), whereas recent
or heavy users were impaired on a range of Wechsler Adult
Intelligence Scale working memory tasks, with greater fre-
quency and quantity of use correlated with poorer perform-
ance (57). Impaired working memory persisted for a few weeks
in some studies (65) but appears to mostly resolve with longer
periods of abstinence (35,55,57,67,85).
For other memory function, see Supplement 1.
Attention
Impaired attention has been considered a hallmark of the
intoxicating effects of cannabis. Further evidence has accumu-
lated in support of acute exposure to cannabinoids impairing
focused, divided, or sustained attention, often in a dose-
dependent manner (36,37,42,43,68,70,71,86–88). In cases
where lesser impairments were observed, this may be due to
the development of tolerance among daily users (76,89,90).
Previous evidence for deficits in attention after chronic cannabis
exposure was mixed, but more recent studies provide some
clarity. Numerous studies report impairment in adolescent and
adult cannabis users with a wide range of exposure as well as
former users abstinent for several weeks on measures of
sustained and divided attention, processing speed, rapid visual
information processing, visual search, tracking, trail making,
and paced serial addition (46,54,55,57,61,91–94). Users absti-
nent for 23 days remained impaired relative to control subjects
despite improvements in sustained and divided attention with
increasing abstinence (91) with poor attentional performance
associated with younger age of onset in this study (91) and
another study of adolescents abstinent for 30 days (95).
However, no difference between abstinent former users and
control subjects on broader measures of attention was also
reported (57,63,64,79,95). Therefore, cannabis-related atten-
tional impairment may reflect residual effects that dissipate
gradually as cannabinoids are cleared from the body
(Supplement 1).
Attentional Bias. Greater attentional bias to cannabis-
related stimuli has been noted in chronic cannabis users
(96–102) and during acute intoxication in individuals with lower
CBD/THC ratios in hair (102). There are no studies of abstinent
users after cessation of use, which may be a particularly
important target for future research to strengthen the efficacy
of treatment programs aimed at maintaining abstinence.
Psychomotor Function
Finger tapping, critical tracking, choice reaction time tasks,
and digit-symbol substitution tasks have been used to meas-
ure psychomotor function. In infrequent users, smoked or
vaporized cannabis impaired critical tracking (42,89,103,104),
affected reaction time and motor control in a dose-dependent
manner (70), and disrupted motor function in a task with a
motivational component (105). In heavy users, high-dose
smoked cannabis resulted in more collisions in a virtual maze
task (106) but did not affect critical tracking (89,90). Oral
administration of THC [or IV (37)], nabilone, or dronabinol
impaired psychomotor function in seven of eight studies
(37,43,68,74,76,77,107), with only one study finding no sig-
nificant impairment (73). Findings regarding the chronic effects
of cannabis on psychomotor function are mixed, being
reported as impaired (51,54,80,108), improved (48), and unaf-
fected (46,78). Psychomotor function was impaired in users
abstinent for 23–35 days (57,65,67,91), with a trend also after
12 months of abstinence (finger tapping) (64). The weight of
evidence suggests that psychomotor function is affected by
acute intoxication and that this likely persists for some time
after chronic cannabis exposure.
Executive Function
Planning, Reasoning, Interference Control, and Prob-
lem Solving. On similar tasks of planning, reasoning, inter-
ference control, and problem solving, THC administration was
found to impair performance in some studies (38,41,103,
104,106,109), but not others (39,86,89), equally across samples
of occasional, moderate, and heavy users. Impaired perform-
ance may depend on extent of prior exposure, route of
administration, dose delivered, and blood cannabinoid concen-
trations at baseline and after dosing (89). With regard to the
chronic effects of cannabis, numerous studies reported null
findings in case-control comparisons (46,54,66,81,95,98,
110,111), whereas several others found cannabis-related defi-
cits in heavy users (53,78,83,112), including adolescents (113),
early-onset but not late-onset adult users (114), and older users
(57), and associated with persistent use in a longitudinal study
(60). Impaired executive function was evident despite intact
performance on other cognitive tasks (48,82) and associated
with self-reported problems related to cannabis use (115).
Studies in which executive dysfunction was detected tended
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to have older samples than the studies in which no impairments
were observed, which included predominantly adolescent and
young adult users. It may be that executive dysfunction
becomes more evident beyond the period of maturation of
the frontal lobes, perhaps reflecting perturbed neurodevelop-
ment. Consistent with this interpretation, three abstinence
studies reported no group differences relative to control sub-
jects in younger samples (65,85,95), whereas persistent exec-
utive dysfunction was observed in users abstinent for $28 days
aged 35–50 years (57) and in users abstinent for 12 months
aged 38–51 years (64), where impaired performance on block
design tests was the only significant difference detected
between abstinent users and their nonuser twins. Older users
have also been exposed to far more cannabis use over the
lifetime.
Inhibition. Measures of inhibition are derived from para-
digms such as go/no-go or stop-signal reaction time tasks.
Acute administration of THC has consistently been reported to
increase stop-signal reaction time in both occasional and
heavier cannabis users (42,89,104,109). Findings in chronic
users are more mixed (45,50,54,56,82,116–118) (Supplement 1).
Verbal Fluency. Three studies reported no effect on
verbal fluency during acute intoxication with THC or cannabis
(36,38,44), but there has been little consistency regarding
chronic or abstinence effects (44,48,51,53,54,61,65,67,85,
93,110,119) (Supplement 1). The findings suggest that if verbal
fluency is impaired in cannabis users, it is more likely to be in
older individuals with longer durations of exposure, whereas in
younger users, impairment in verbal fluency may depend on
intellectual functioning and on the task employed.
Time Estimation. The subjective effect of cannabis dis-
torting time is well known, but objective evidence from new
studies of time estimation is limited (Supplement 1).
In summary, executive function subdomains are differentially
affected by acute administration and chronic exposure to
cannabis. There are clear acutely impairing effects on inhibition,
whereas planning, problem solving, reasoning, and interference
control are inconsistently impaired, and the moderators of
impaired performance require further investigation. The latter
subdomains may be more affected in older chronic users or
with greater exposure to cannabis. Literature assessing recov-
ery of executive functions with abstinence is very sparse, and
this is an important area for optimizing treatment programs for
cannabis dependence. For example, one study found that poor
neurocognitive performance was associated with relapse to
cannabis use at 1-year follow-up in adolescents (95).
Decision Making, Reward Processing, and Delay
Discounting
Measures of risky and impulsive decision making include
performance on the Iowa Gambling Task, delay discounting
tasks, and behavioral risk-taking tasks. Some studies found
that acute administration of THC adversely affected decision
making by altering sensitivity to reward and punishment
and increasing risk taking in infrequent (120) and regular
users (106,121,122), but not all studies found impaired
decision making (103,109). Evidence for effects of chronic
cannabis use on decision-making is mixed. Although several
studies reported poorer decision-making performance across a
range of tasks (48,78,82,117,123,124), especially decreased
sensitivity to loss and greater sensitivity to gains (123),
clear group differences were not found in other studies
(45,50,94,125–127). Cognitive flexibility in decision making is
also affected by chronic cannabis exposure (45,113,116). Behav-
ioral risk taking was greater in adolescents with a mean period of
abstinence of 53 days (85) and associated with extent of prior
exposure in users with an abstinence period of 25 days (127), but
was unaffected in other studies of current users (50,56,125). No
delay discounting performance differences were found between
current and abstinent users and control subjects (128). Thus,
risky decision making and sensitivity to reward are increased
during acute intoxication. Despite a large number of studies of
chronic users in the past decade, the extent to which these
effects persist in chronic or abstinent users remains unclear.
DISCUSSION
In general, the literature on the cognitive effects of cannabis
exposure continues to be plagued with complexity in terms of
heterogeneity of both the extent of cannabis exposure in the
samples assessed and the means of assessing cognitive
function (18–21). The nature of the samples recruited and
the way in which prior exposure to cannabis is quantified
affect interpretation of findings for acute and chronic effects.
In studies of chronic users, associations with frequency of use
are more likely to reflect the residual effects of acute or
subchronic intoxication, associations with dose of exposure
may reflect residual or cumulative effects, and associations
with the duration of use are likely to indicate more persistent
cannabis-related alterations (20). These parameters may also
interact with the neurodevelopmental period during which
regular cannabis use is started, and increasing consideration
has been given to age of onset effects and assessing
adolescent users. Potential sex differences are insufficiently
addressed in studies of predominantly male cannabis users
(75% of studies reviewed), although many argue that this
overrepresentation matches the sex distribution of cannabis
users in the general population (129). Where sex effects were
tested (12% of studies), very few were found (see
Supplements 1 and 2). Evidence for sex differences in
cannabinoid metabolism, action, and brain morphology in
cannabis users (130–132) suggests that future research should
further investigate these differences in relation to cognition,
both following acute administration and with chronic expo-
sure. Several key issues are critical to consider further.
Dose, Route of Administration, and Tolerance
Effects
Acute administration studies often, but inconsistently, report
dose-dependent effects (Supplements 1 and 2 contain further
details of doses administered). Discrepancies may be due to
differing routes of administration, with IV, smoked, and
vaporized cannabinoids exerting more immediate but
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shorter-lasting effects than effects following oral or sublingual
administration. The duration of impaired cognition after acute
administration has not been further investigated; most studies
conducted a single assessment immediately after or within
2–3 hours of dosing. The development of tolerance is often
assumed to occur in frequent or dependent users and is
inferred to explain modest effects in some studies, with
supportive reference to preclinical literature and some prior,
but limited, human studies. Most studies of acute adminis-
tration examined effects in a single sample of control subjects
or occasional or infrequent users (23 studies), or a single
sample of regular, frequent, or daily users (11 studies),
whereas only 4 studies directly compared effects in cannabis
users versus control subjects (2 studies; 37,87) or in frequent
versus infrequent users (2 studies; 89,149) (Supplement 2).
These latter studies reported blunted impairing effects in regular
or frequent users of acute smoked cannabis on critical tracking
and divided attention or of IV THC on spatial working memory,
verbal memory (inconsistently), and time estimation. Tolerance
may occur in other cognitive domains, but the research over the
past decade has not significantly advanced knowledge of
tolerance effects beyond the limited previous evidence in
humans (87). Although cognitive impairment after acute canna-
binoid exposure may be blunted in regular users, substantial
further evidence has accumulated that it nevertheless still exists
across multiple domains (psychomotor, attention, and, incon-
sistently, memory) and with potential real-world effects on
complex tasks involving these domains, such as driving (133).
Specificity to Cannabis and Potential Confounds
The literature continues to be riddled with a range of potential
confounds that may affect specific attribution of impairment to
cannabinoids, including largely premorbid functionality and
other substance use. The strongest design to address these is
a large-sample prospective study that controls for cognitive
ability assessed before initiation of cannabis use, years of
education, and other substance use. One such study examined
neuropsychological change from childhood to age 38 and found
that persistent cannabis use or dependence was associated
with an IQ decline of 6 points; this reflected broad decline in
functioning not specific to any particular cognitive domain;
cessation of use did not restore IQ in adolescent-onset users;
and specificity to persistent cannabis use was determined by
ruling out effects caused by recent cannabis use and persistent
tobacco, alcohol, or other drug use (60). Two further studies
controlling for premorbid function showed that adolescent
cannabis users showed impaired verbal learning and memory
(47) and immediate and delayed memory and processing speed
(79), whereas former users did not differ from control subjects
(79). Numerous studies have not controlled for premorbid
functioning or ascertained current intellectual functioning;
.50% of studies did not report IQ or years of education. Where
groups were matched on IQ or IQ was controlled for in analyses,
persistent impairments to cognition were identified for immedi-
ate and delayed memory (79), verbal learning and memory
(39,61), verbal fluency, attention, and executive function (61)
[although not in other studies (84,128)].
Alcohol and tobacco use as well as other illicit substance
use are common in cannabis users, and a disconcerting
number of studies continue to fail to report or account for
this (Supplements 1 and 2). Means of dealing with these
potential confounds include applying a heterogeneous range
of exclusion criteria, often poorly specified; matching compar-
ison groups on levels of use; and covarying for other
substance use but with wide-ranging metrics (e.g., quantity/
frequency measures, lifetime use, dependence/abuse scores).
Mostly, the cognitively impairing effects of chronic cannabis
use have held after controlling for other substance use, but not
in all studies (Supplement 1). Greater standardization of not
only cannabis use metrics across studies but also tobacco,
alcohol, and other drug use would enable better character-
ization of the specificity of cannabis effects. Further research
to examine additive, interactive, or synergistic effects of
cannabinoids with other substances is required.
Persistence or Recovery of Function With
Abstinence
Recovery of function after prolonged abstinence remains con-
tentious. The persistence of impairments or recovery of cogni-
tive function after a period of abstinence .24 hours, most often
for several weeks (21–35 days; only a few went beyond this
period) was examined in 18 new studies. In 11 studies, cross-
sectional comparisons were performed of former users (absti-
nent 7 days to .1 year) and current users or nonuser control
subjects; 9 of these studies assessed adolescents or young
adults. Seven were prospective studies, assessing cannabis
users at baseline and at follow-up (with some intervening
measures) over periods ranging from 21 days to 4–8 years of
abstinence. Although this is a stronger design, there remains a
conspicuous paucity of these studies, as two were confounded
by concomitant pharmacologic treatments (63,93).
Cross-sectional studies report persistent impairing effects
on some aspects of attention, verbal and working memory,
and psychomotor speed in adolescents abstinent for 28 days
(65) and 35 days (67), but not on other aspects of these and
other cognitive domains. Poor performance was associated
with lifetime cannabis exposure (65) or an earlier age of use
onset in adolescents with 30 days of abstinence (95) and
predicted relapse to cannabis use during a 1-year follow-up
(95). Even after 53 days of abstinence, adolescents showed
impaired working memory and risk taking (85). Young adults
abstinent for up to 4 weeks showed poorer verbal fluency
relative to control subjects (119) and nonsignificantly poorer
performance on a gambling task, associated with prior quan-
tity of weekly cannabis use (127). Older adults abstinent for
.28 days were impaired on executive function and information
processing but not attention and working memory (57). Lyons
et al. (64) argued that their study of monozygotic twins,
discordant for cannabis use with .12 months abstinence,
provides evidence against long-term effects of cannabis on
cognition, despite finding impaired performance on block
design tests and trends toward poorer long delay and cued
verbal recall and poorer finger tapping performance in the
former users. Such studies offer a rare opportunity to control
for underlying vulnerability to cannabis use, which may never-
theless interact with effects of persistent use.
In the prospective studies, only two controlled for premor-
bid function; one found that adolescent former users did not
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differ from control subjects on any cognitive measures (79),
whereas another large and well-controlled prospective study
showed that cannabis use before the age of 18 resulted in
greater decline in IQ by age 38 persisting even after cessation
or reduction of use in the past year (60). Poor verbal learning
improved in adolescents by 2 weeks of abstinence, but visual
search remained impaired at 3 weeks relative to baseline (55).
An adult sample showed improvements in critical tracking and
divided attention with increasing abstinence periods over 8–23
days, but the sample subjects remained impaired relative to
control subjects; withdrawal and age of onset effects were
observed (91). In a large prospective study following a sample
across three waves of data collection spaced 4 years apart,
former heavy users abstinent for $12 months improved rela-
tive to ongoing heavy users on immediate verbal memory and
did not differ from nonusers on any cognitive measure (66).
Given the plasticity of the human brain, recovery of
function might be anticipated, and consistent with previous
findings (134,135), the evidence from some (but not all) of
these recent studies suggests that verbal learning and
memory impairment may recover with prolonged abstinence.
Yet evidence for persistent cognitive dysfunction continues to
emerge. Neither the precise cannabis use metrics required for
the persistence of cognitive deficits nor the neural mecha-
nisms underlying the persistence of deficits have been
elucidated. The latter likely include neurotransmitter system
dysfunction (136–138) and regional brain structural and con-
nectivity alterations (32,139), which may take significant time
to be restored to pre–cannabis use integrity and functionality
[however, see Yücel et al. (140)]. Previous studies using
sensitive measures of brain function detected duration of
exposure-related impaired attentional processes in 2-year
abstinent users (141). Further well-controlled prospective
studies monitoring restoration of brain function and structure
from current use through cessation of use and over prolonged
abstinence are urgently needed.
CONCLUSIONS
Further significant evidence has emerged supporting the
finding that acute and chronic exposure to cannabinoids
impairs cognition, especially in the domains of verbal learning,
memory, and attention (Table 2). Mixed evidence across the
range of other cognitive domains is likely due to ongoing
heterogeneity in the cognitive tests employed, prior cannabis
use histories, and the assessment of cannabis use metrics as
well as the neurodevelopmental stage at both onset and
cessation of cannabis use. Nevertheless, it is clear from the
literature reviewed that cognitive impairment on a range of
domains can persist beyond the period of acute intoxication
and potentially affect daily functioning in cannabis users and
hence the range of adverse educational and other psychoso-
cial outcomes identified as associated with frequent use, in
particular for adolescent users (17). Multiple potential moder-
ators of cannabinoid effects remain underinvestigated, includ-
ing premorbid and other individual differences, genetic factors,
sex, psychopathology, and polydrug use, and few studies
consider the range of compounds in cannabis that interac-
tively moderate the effects of THC, despite increasing interest
in CBD. Further prospective and mechanistic studies are
required to understand the impact of cannabinoids during
brain maturation in adolescence through young adulthood and
interacting with normal and abnormal aging processes in later
years. The time course and moderators of potential recovery
of cognitive function necessitate more precise delineation. In
light of increasing trends toward legalization or medicalization
of cannabis, it is imperative to research further the parameters
of cannabis use that result in impairment and the potential for
protection from cognitive harm by CBD (evidence is growing
but is not definitive) such that harm minimization strategies
may be implemented, and to understand the therapeutic
parameters of any of the cannabinoids to enable the benefits
of medications without concomitant brain and cognitive harm.
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Table 2. Key Findings for Cognitive Impairment in Cannabis
Users
Acute Effects of Cannabis on Cognition
Impaired verbal learning and memory
Impaired working memory and other memory functions
Impaired attention, task and dose dependent
Impaired inhibition, less so for other executive functions
Impaired psychomotor function
Chronic Effects of Cannabis on Cognition
Impaired verbal learning and memory
Impaired attention and attentional bias
Possible impaired psychomotor function
Mixed evidence for executive function and decision making
Most associated with cannabis use parameters, particularly frequency
of use and age of onset
Recovery of Function With Abstinence
Likely persistent effects on attention and psychomotor function
Possible persistent effects on verbal learning and memory
Evidence insufficient and mixed
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